The portfolio maintains a sizable cost advantage over competitors, priced within the least expensive fee quintile among peers.
Franklin Genomic Advancements ETF HELX
Morningstar’s Analysis HELX
Will HELX outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 44.0
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
---|---|---|---|
Medpace Holdings Inc | 7.98 | 734,499 | Healthcare |
Thermo Fisher Scientific Inc | 4.91 | 451,628 | Healthcare |
Vertex Pharmaceuticals Inc | 4.78 | 440,137 | Healthcare |
Regeneron Pharmaceuticals Inc | 4.55 | 418,275 | Healthcare |
Danaher Corp | 4.25 | 391,308 | Healthcare |
Eli Lilly and Co | 4.24 | 389,996 | Healthcare |
Krystal Biotech Inc | 4.09 | 375,933 | Healthcare |
Bruker Corp | 3.20 | 294,877 | Healthcare |
Samsung BioLogics Co Ltd | 3.05 | 280,645 | Healthcare |
Natera Inc | 2.96 | 272,756 | Healthcare |